Am J Pathol 2011, 178:1009–1020.PubMedCrossRef 14. Kanojia D, Garg M, Gupta S, Gupta A, Suri A: Sperm-associated antigen 9, a novel biomarker for early detection of breast cancer. Canc Epidemiol Biomarkers Prev 2009, 18:630–639.CrossRef 15. Cleator S, Heller W, Coombes RC: Triple-negative breast cancer: therapeutic options. Lancet Oncol 2007, 8:235–244.PubMedCrossRef
16. Egland KA, Kumar V, Duray P, Pastan I: Characterization of overlapping XAGE-1 transcripts encoding a cancer testis antigen ATM inhibitor expressed in lung, breast, and other types of cancers. Mol Canc Ther 2002, 1:441–450. 17. Grigoriadis A, Caballero OL, Hoek KS, et al.: Cilengitide cost CT-X antigen expression in human breast cancer. Proc Natl Acad Sci U S A 2009, 106:13493–13498.PubMedCrossRef 18. Brabletz T: EMT and MET in metastasis: where are the cancer stem cells? Canc Cell 2012, 22:699–701.CrossRef 19. Germano S, Kennedy S, Rani S, et al.: MAGE-D4B is a novel marker of poor
prognosis and potential therapeutic target involved in breast cancer tumorigenesis. Int J Canc 2012, 130:1991–2002.CrossRef 20. Atanackovic D, Hildebrandt Y, Jadczak A, et al.: Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells. Haematologica 2010, 95:785–793.PubMedCrossRef 21. Cronwright G, Blanc KL, Gotherstrom C, Darcy P, Ehnman M, Brodin B: Cancer/testis antigen expression in human mesenchymal Vactosertib clinical trial stem cells: down-regulation of SSX impairs cell migration and matrix metalloproteinase
2 expression. Canc Res 2005, 65:2207–2215.CrossRef 22. Neesse A, Gangeswaran R, Luettges J, Feakins R, Weeks ME, Lemoine NR, Crnogorac-Jurcevic T: Sperm-associated antigen 1 is expressed early in pancreatic tumorigenesis and promotes motility of cancer cells. Oncogene of 2007, 26:1533–1545.PubMedCrossRef 23. Xin-Li L, Dan Z, Da-Peng S, Yang W, Yan L, Feng-Qi Q, Ping M: Adenovirus-mediated delivery of CALR and MAGE-A3 inhibits invasion and angiogenesis of glioblastoma cell line U87. J Exp Clin Canc Res 2012, 31:2–10.CrossRef Competing interests The authors declare that they have no competing interests. Authors’ contributions AS performed SPAG9 expression studies and drafted the manuscript. SA carried out transfection studies and in vitro and in vivo experiments. AV performed RT-PCR analysis. DP performed real time PCR. SS and NJ analyzed the data and prepared the figures. AKA and NKL helped in drafting the manuscript. AS conceived the study, designed the experiments and prepared the manuscript. All authors read and approved the final manuscript.”
“Background Gastric cancer and cancer of the gastro-oesophageal junction (GEJ) are a significant global health problem, representing the fourth most common cancer diagnosed worldwide [1]. The prognosis for these patients remain poor, as the majority of them are diagnosed with locally advanced or metastatic disease with a median survival of 7–10 months [2].